BioLargo, Inc.
BLGO · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,103 | $2,777 | $3,269 | $3,657 |
| % Growth | -60.3% | -15.1% | -10.6% | – |
| Cost of Goods Sold | $731 | $1,356 | $1,781 | $1,907 |
| Gross Profit | $372 | $1,421 | $1,488 | $1,750 |
| % Margin | 33.7% | 51.2% | 45.5% | 47.9% |
| R&D Expenses | $615 | $535 | $791 | $784 |
| G&A Expenses | $0 | $2,600 | $2,383 | $2,477 |
| SG&A Expenses | $3,088 | $2,688 | $2,559 | $2,582 |
| Sales & Mktg Exp. | $0 | $88 | $176 | $105 |
| Other Operating Expenses | $3,118 | $0 | $0 | $0 |
| Operating Expenses | $6,821 | $3,223 | $3,350 | $3,366 |
| Operating Income | -$6,449 | -$1,802 | -$1,862 | -$1,616 |
| % Margin | -584.7% | -64.9% | -57% | -44.2% |
| Other Income/Exp. Net | -$30 | -$80 | -$59 | -$116 |
| Pre-Tax Income | -$6,479 | -$1,882 | -$1,921 | -$1,732 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6,479 | -$1,192 | -$1,155 | -$1,014 |
| % Margin | -587.4% | -42.9% | -35.3% | -27.7% |
| EPS | -0.02 | -0.004 | -0.004 | -0.003 |
| % Growth | -412.8% | -2.6% | -11.8% | – |
| EPS Diluted | -0.02 | -0.004 | -0.004 | -0.003 |
| Weighted Avg Shares Out | 308,974 | 303,197 | 301,274 | 301,274 |
| Weighted Avg Shares Out Dil | 308,974 | 303,197 | 301,274 | 301,274 |
| Supplemental Information | – | – | – | – |
| Interest Income | $80 | $0 | $0 | $0 |
| Interest Expense | $144 | $80 | $65 | $127 |
| Depreciation & Amortization | $18 | $81 | $58 | $67 |
| EBITDA | -$6,317 | -$1,721 | -$1,798 | -$1,538 |
| % Margin | -572.7% | -62% | -55% | -42.1% |